BTG reports positive results from TheraSphere clinical study for HCC using IO Loop

11 June 2017 (Last Updated June 11th, 2017 18:30)

UK-based healthcare firm BTG has reported a favourable outcome from a clinical study conducted to evaluate IO Loop service in primary hepatocellular carcinoma (HCC) patients being treated with TheraSphere 90Y transarterial radioembolisation therapy.

UK-based healthcare firm BTG has reported a favourable outcome from a clinical study conducted to evaluate IO Loop service in primary hepatocellular carcinoma (HCC) patients being treated with TheraSphere 90Y transarterial radioembolisation therapy.

BTG’s TheraSphere 90Y glass microspheres are designed to deliver high doses of radiation to liver tumours without affecting normal tissue, while its IO Loop powered by HealthLoop is a digital engagement platform developed to educate, engage and monitor patients.

The results indicated a sustained quality of life throughout the three months after treatment. They also showed completion of 71% of all automated delivery of digital patient reported outcome (PRO) surveys and a mean overall patient engagement rate of 65%.

BTG Global Market Access vice-president Lisa Hayden said: "IO Loop offers patients and their clinicians a service that brings them closer together and utilises the power of this collaboration to support better clinical and health-related outcomes.

“This study demonstrates that using IO Loop to capture PROs after treatment with TheraSphere can help clinicians efficiently report patient experience, a particularly important need given reimbursement requirements.”

"IO Loop offers patients and their clinicians a service that brings them closer together and utilises the power of this collaboration to support better clinical and health-related outcomes."

The multi-centre pilot study assessed the effectiveness of IO Loop to educate, engage and measure health-related quality of life (HRQoL) in 41 patients who were enrolled on a digital patient engagement platform.

The programme was used to guide the patients from 21 days pre-treatment with TheraSphere, through to 90 days post-treatment.

During the treatment and near-term follow-up period, patients were surveyed at regular intervals to analyse preservation of physical, functional and symptom-related QoL.

The results obtained using IO Loop demonstrated stable QoL and low side-effect concerns compared to other traditional cancer treatment options.

Designed to connect physicians and patients during treatment, IO Loop is said to enable easy patient preparation, tracking and report of symptoms, early awareness, and timely management of complications.